Skip to content
value.today

NephroDI Therapeutics, Inc.

🇺🇸 Philadelphia, Pennsylvania, USAPharmaceuticalsFounded 2017
Total raised
$4 M
2 rounds on record
Latest round
$2 M
Jun 2024
First round on record
Feb 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of NephroDI Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2024$2 MNo. 2$2 to $10 million

NephroDI Therapeutics, Inc.: Raise no. 2, Jun 2024

Investors in this round

2 investors had bought by the notice of Jun 18, 2024: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$2,113,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeff M. Sands, M.D. · Executive Officer
  • Rachael Hagan · Executive Officer, Director
  • Bibhash M. Mukhopadhyay · Director
  • Michael Grissinger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Estimated amount assumes the Issuer will raise the Total Offering Amount”

Signed by Rachael Hagan, President. Newest notice filed Jun 18, 2024. Read the notice at the SEC.

equitySEC
Feb 2021$2 MNo. 1Under $2 million

NephroDI Therapeutics, Inc.: Raise no. 1, Feb 2021

Investors in this round

1 investor had bought by the notice of Feb 23, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeff M. Sands, M.D. · Executive Officer
  • Rachael Hagan · Executive Officer, Director
  • Chris M. Garabedian · Director
  • Donna M. See · Director
  • Fred M. Callori · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Rachael Hagan, President. Newest notice filed Feb 23, 2021. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • NephroDI Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2024).

    SEC Form D · Jun 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of NephroDI Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by NephroDI Therapeutics, Inc.
NameRoleNamed in
Jeff M. Sands, M.D.Executive officerJun 2024
Rachael HaganExecutive officerJun 2024
Bibhash M. MukhopadhyayDirectorJun 2024
Michael GrissingerDirectorJun 2024
Rachael HaganDirectorJun 2024
Chris M. GarabedianDirectorFeb 2021
Donna M. SeeDirectorFeb 2021
Fred M. CalloriDirectorFeb 2021